Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting

About this update from Rigel Pharmaceuticals, Inc.

[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., June 1, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming poster presentation highlighting the Company's IRAK1/4 program at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2023, in Chicago, IL, and virtually.\nRigel continues to advance the open-label, Phase 1b clinical trial of R2891, an investigational, potent, and selective IRAK1/4 inhibitor, in patients with lower-risk myeloid dysplastic syndrome (LR-MDS) who are refractory/resistant to prior therapies. Rigel has completed enrollment of the first cohort of the trial and enrollment of the second cohort is underway.\nPoster Presentation Details:\nAbstract #: TPS7085Title: Phase 1b Clinical Study of IRAK 1/4 Inhibition for Low-Risk Myelodysplastic Syndromes Refractory/Resistant to Prior TherapiesLead Author: Guillermo Garcia-Manero, M.D., Professor, Chief Section MDS, Deputy Chair Translational Medicine, Leukemia, University of Texas MD Anderson Cancer CenterSession Name: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and AllotransplantDate: June 5, 2023Presentation Time: 8:00-11:00 AM CDTLocation: Hall A\nThe conference abstract can be accessed here.\nTo learn more about Rigel Pharmaceuticals and the Company's clinical and commercial hematology/oncology portfolio visit booth #20134 during ASCO.\nAbout R289R289 is a prodrug of R8351, an IRAK1/4 dual inhibitor, which has been shown in preclinical studies to block inflammatory cytokine production in response to toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) family signaling. TLRs and IL-1Rs play a critical role in the innate immune response and dysregulation of these pathways can lead to various inflammatory conditions. Chronic stimulation of both these receptor systems is thought to cause the pro-inflammatory environment in the bone marrow responsible for persistent cytopenias in lower-risk MDS patients2.\nAbout RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potent...

More updates from Rigel Pharmaceuticals, Inc.